Brief: Actinium Announces Data From Phase 1 Actimab-A Clag-M Combination Trial
03/11/2022 14:41
Nov 3 (Reuters) - Actinium Pharmaceuticals Inc ATNM.A :
* ACTINIUM ANNOUNCES POSITIVE 1-YEAR AND 2-YEAR OVERALL
SURVIVAL
DATA FOR PATIENTS WITH RELAPSED OR REFRACTORY AML IN PHASE 1
ACTIMAB-A CLAG-M COMBINATION TRIAL
* ACTINIUM PHARMA - 53% 1-YEAR OVERALL SURVIVAL AND 32%
2-YEAR
OVERALL SURVIVAL ARE APPROXIMATELY DOUBLE OUTCOMES WITH CURRENT
APPROACHES IN TRIAL
* ACTINIUM PHARMACEUTICALS INC - MEDIAN OVERALL SURVIVAL
(OS) OF
12 MONTHS AMONGST ALL PATIENTS IN TRIAL
* ACTINIUM PHARMACEUTICALS INC - OVERALL RESPONSE RATE (ORR)
OF
67% ACROSS ALL DOSE COHORTS IN TRIAL
Source text for Eikon: ID:nPn69NSh5a
Further company coverage: ATNM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities